Friday | BusinessWeek
S&P Picks and Pans: Freddie, Abbott, JetBlue, ING
We believe FRE will face a more difficult funding environment in coming months than just a few months ago.
Boston Scientific Corporation - SWOT Analysis - New Research Report on Companies and Markets
The report examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
After Hours: Abbott rises following FDA stent approval; tech stocks tick up
Abbott Laboratories shares rose Wednesday evening after regulators approved the use of one of its medical devices, and Dell Inc.
Boston Scientific Announces First Enrollment For The FASt-Ibp CRM Study
Main Category: Cardiovascular / Cardiology Also Included In: Clinical Trials / Drug Trials Article Date: 26 Jun 2008 Boston Scientific Corporation announced that the first patients were enrolled in the Cardiac ...
Boston Scientific sells investment to pay debt
Boston Scientific Corp. has agreed to sell pieces of its investment portfolio through a pair of transactions that will raise a total $140 million before taxes and help pay off debt, but also force the medical ...
Dented Stent Market Drives Cordis Turnovers
The management at Cordis seems to be loosing heart. The Johnson & Johnson subsidiary has had a round of significant turnover amongst its upper management in recent months with the latest announcement coming ...
Boston Scientific spent $400,000 on lobbying in 1Q
Medical device maker Boston Scientific Corp. spent $400,000 lobbying the federal government in the first quarter, according to a recent disclosure form.
BSX Fitch Rating Rises To Stable
Fitch Ratings has changed its rating outlook on Natick-based Boston Scientific Corp.
Lima Memorial Hospital has changed a lot since James Tobin was born inside more than six decades ago.
Corporate Express, Inc. > Use of, or registration on, this site constitutes acceptance of our User Agreement and Privacy Policy .
Fitch Ups Boston Scientific Outlook On Heart Device Market
Fitch Ratings raised the outlook on Boston Scientific Corp. to stable from negative given the medical device maker's progress in stabilizing its drug-coated stent and cardiac rhythm management device markets.
Tobin To Head BSX Into 'Foreseeable Future'
Jim Tobin, president and CEO of Natick-based Boston Scientific Corp. , will be head of the company "for the foreseeable future," the company said.
Holy crud! It would have been hard to believe back in April 1998 that a stock index tracking America's largest companies -- Schlumberger , Boston Scientific , Anheuser-Busch , et al -- would get beaten by a ...
Medtronic Sticks It to Boston Scientific
Now it's sticking it to Boston Scientific in the courtroom. On Tuesday, a jury found that Boston Scientific's balloon catheters and stent delivery systems infringe on three of Medtronic's patents.
San Diego--- Boston Scientific Completes Acquisition of CryoCor
Boston Scientific Corporation and CryoCor, Inc. today announced that Boston Scientific has completed its acquisition of CryoCor.
Medtronic Awarded $250 Million Damages in Patent Case against Boston Scientific
Medtronic, Inc. today announced that a federal jury found that Boston Scientific Corporation has infringed three patents owned by Medtronic, and awarded Medtronic $250 million in damages.
Boston Scientific's struggle to maintain the entrepreneurial spirit Boston Scientific Corp.
Medtronic's Endeavors Look Good
Fourth-quarter revenue was up a solid 18% year over year. The company saw double-digit gains in all divisions except its cardiac rhythm segment, which registered more modest growth of 6%. Unfortunately, it is ...
Multi-Center Patient Registry Supports Safety and Clinical Utility of ...
Results from the registry were presented by Yang K. Chen , M.D., Division of Gastroenterology & Hepatology, University of Colorado at Denver and Health Services Center and lead investigator, at Digestive ...
Timing of Medftronic defibrillator news is no shock
“With the cost-conscious society we have right now, that's very important.”
It doesn't hurt to launch a new medical device right before a large meeting of doctors who actually use the product begins. via Star Tribune